Floatz logo

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer

Nivolumab

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Nivolumab cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Irinotecan
M.D. Anderson Cancer Center
Phase 2CCC
Trifluridine
M.D. Anderson Cancer Center
Phase 2CCC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2CCC
TIPIRACIL
M.D. Anderson Cancer Center
Phase 2CCC
BMS 986253
Yana Najjar
Phase 1CC

Same molecule, other indications

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human CC chemokine receptor CCR8) (human-Mus musculus monoclonal BMS-986340 ?1-chain), disulfide with human-Mus musculus monoclonal BMS-986340 ?-chain, dimer is also rated in:

colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →
pancreatic adenocarcinomaDormant
B
Indicative ·
58 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →